BIOACTIVE POLYPHENOLS FROM ANACARDIUM OCCIDENTALE LINN LEAVES AND THEIR EFFECTS ON A-AMYLASE AND DIPEPTIDYL PEPTIDASE IV ACTIVITIES

BY

NUR IMANINA BINTI ABDULLAH THAIDI

A thesis submitted in fulfillment of the requirement for the degree of Master of Science (Biotechnology)

Kulliyyah of Science
International Islamic University Malaysia

NOVEMBER 2019
Anacardium occidentale Linn. (A. occidentale L.) or cashew tree is one of the famous tropical plants among various ethnics in Malaysia. Its leaves are commonly consumed as ulam in Southeast Asia. Its leaves possess an excellent source of bioactive compounds, which are associated with numerous health benefits, including antidiabetic potency for type 2 diabetes mellitus (T2DM). The management strategies for T2DM include maintaining the postprandial blood glucose level through the inhibition of α-amylase and to prevent the hydrolysis of glucagon-like peptide-1 (GLP-1) through the inhibition of dipeptidyl peptidase IV (DPPIV). The DPPIV is a serine protease that localizes on cell surfaces and responsible for the rapid degradation of incretins such as a gastric inhibitory peptide, whilst α- amylase is served as the necessary digestive enzymes by involving in the breaking of long-chain carbohydrates into small pieces before absorption in the intestine. In this study, free, soluble ester and insoluble bound phenolic fractions from young and mature leaves of A. occidentale L. were extracted and analyzed for their phenolic compounds concentration using high-performance liquid chromatography (HPLC). Subsequently, all fractions were investigated for their inhibitory effects on α-amylase and DPPIV enzyme activities. Both free (72.45 ± 3.6%) and soluble ester (83.40 ± 4.7%) phenolic fractions in the mature leaves extracts had significantly demonstrated higher α-amylase inhibitors than the young leaves. Likewise, soluble ester (4.09 ± 0.34 µg/ml) and insoluble bound (4.87 ± 0.32 µg/ml) phenolic fractions in the mature leaves extracts were significantly more effective in inhibiting DPPIV than the young leaves. As for fractions comparison, insoluble bound derived from the young leaves extract was a more potent α-amylase inhibitor than free and soluble ester phenolic fractions (p<0.001). Soluble ester and insoluble bound phenolic fractions showed stronger inhibitors of DPPIV than the free phenolic (p<0.001), based on the maturity of the leaves. The interaction between fraction and maturity were significantly different in both young and mature leaves of A. occidentale L. according to the α- amylase, and DPPIV inhibition analyses (p<0.001). In conclusion, this study showed that A. occidentale L. leaves extracts possessed inhibition properties in α- amylase and DPPIV activities, which further may potentially be exploited in clinical study as an antidiabetic for type 2 diabetes mellitus.
خلاصة البحث

إن نبات الأناكارديوم أوكسيدينتالي لين (Anacardium occidentale Linn.)، المعروف بـ شجيرة الكاجو، نبات استوائي معروف بين مختلف الأعراق في ماليزيا. تَستَمِتل أوراقها في جنوب شرق آسيا بصورة عامة كواصٍ. تَعتبر أوراق هذه الشجرة مصدرًا ممتازًا للمركبات النشطة البيولوجيا، والتي ترتبط بالعديد من الفوائد الصحية مثل خواصها المضادة لمرض السكري من النمط الثاني (T2DM). تَشمل استراتيجيات إدارة داء السكري الحفاظ على مستوى السكر في الدم بعد الأكل من خلال تثبيت إنزيم ألفا-أميليز ومنع التحلل المائي للجلوكوز مثل الببتيد-1 (GLP-1) بواسطة تثبيت دي بيتيل بيتيداز-4 (DPPIV)، وهو عبارة عن بروتين شيرتي يتواجد على أسطح الخلافا ومسؤول عن التحلل السريع لأسيرين مثل الببتيد المثبط للمعدة. بينما يتم عمل إنزيم ألفا-أميليز كأنزيمات هضمية ضرورية من خلال عملية تخطيط الكوربيهيدرات إلى أجزاء صغيرة قبل هضمها وامتصاصها في الأمعاء. تم في هذه الدراسة استخلاص تحليل إسترات قابلة للذوبان وفيونوات مرتبطية غير قابلة للذوبان من أوراق شجرة الكاجو الصغرى والكبيرة. للتحقق من تراكيز مركبات الفيونول باستخدام الكروماتوغرافيا السائلة عالية الأداء (HPLC). في وقت لاحق تم التحقق من الدافع الإيجابي لجميع الأجزاء على أنواع الأنزيمات ألفا أميليز و DPPIV والإسترات القابلة للذوبان (مستخلصات الأوراق الكبرى تثبيتا أكثر إنزيم ألفا أميليز وبشكل ملحوظ مقارنة بالأوراق الصغرى. وبالمثل كانت الإسترات القابلة للذوبان (مستخلصات الأوراق الصغرى) 0.47±0.32 ميكروغرام/مل للأجزاء الفينولية من الإسترات المرتبطة غير القابلة للذوبان 0.40±0.32 ميكروغرام/مل (p<0.001) للفينولات مرتبطة غير القابلة للذوبان (p<0.001) للفينولات مرتبطة غير القابلة للذوبان مع الإسترات القابلة للذوبان. وأداة الفينولية من المستخلصات الأوراق الصغرى أكثر فعالية في تكون ومع مقارنة بالأوراق الصغرى. أما بالنسبة للمقارنة بين الأجزاء، فإن الإسترات المرتبطة غير القابلة للذوبان المشتملة من مستخلصات الأوراق الصغرى كانت أكثر تثبيتاً للفينولات. إضافة إلى ذلك أظهرت الإسترات القابلة للذوبان والأجزاء الفينولية مرتبطية غير القابلة للذوبان تثبيتاً أقوى لإستريم الفينولات المرتبطة غير القابلة للذوبان. يمكن أيضاً التفاعل بين الإسترات القابلة للذوبان (p<0.001) على حسب توضيح الأجزاء. نجح أيضاً عن التفاعل بين الأجزاء، مستوي محو أوراق اختلافاً كبيراً في كل من الأوراق الصغرى والكبيرة لـ شجرة الكاجو على تحليل تثبيت إنزيمات ألفا أميليز و DPPIV (p<0.001) تمتلك خصائص تثبيت في أنواع ألفا-أميليز و DPPIV، والتي قد يتم استغلالها في العمليات السريرية لإدارة داء السكري من النمط الثاني.
I certify that I have supervised and read this study and that in my opinion, it conforms to acceptable standards of scholarly presentation and is fully adequate, in scope and quality, as a thesis for the degree of Master of Science (Biotechnology)

Normah Haron
Supervisor

Deny Susanti Darnis
Co-Supervisor

Hanapi Mat Jusoh
Co-Supervisor

I certify that I have read this study and that in my opinion it conforms to acceptable standards of scholarly presentation and is fully adequate, in scope and quality, as a thesis for the degree of Master of Science (Biotechnology)

Muhammad Muzaffar Ali Khan Khattak
Internal Examiner

Hasnah Haron
External Examiner

This thesis was submitted to the Department of Biotechnology and is accepted as a fulfilment of the requirement for the degree of Master of Science (Biotechnology)

Mardiana Mohd Ashaari
Head, Department of Biotechnology

This thesis was submitted to the Kulliyyah of Science and is accepted as a fulfilment of the requirement for the degree of Master of Science (Biotechnology).

Shahbudin Saad
Dean, Kulliyyah of Science
DECLARATION

I hereby declare that this thesis is the result of my own investigations, except where otherwise stated. I also declare that it has not been previously or concurrently submitted as a whole for any other degrees at IIUM or other institutions.

Nur Imanina Binti Abdullah Thaidi

Signature ................................. Date ..............................
INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA

DECLARATION OF COPYRIGHT AND AFFIRMATION
OF FAIR USE OF UNPUBLISHED RESEARCH

BIOACTIVE POLYPHENOLS FROM ANACARDIUM OCCIDENTALE LINN. LEAVES AND THEIR EFFECTS ON \(\alpha\)-AMYLASE AND DIPEPTIDYL PEPTIDASE IV ACTIVITIES

I declare that the copyright holder of this thesis is jointly owned by the student and IIUM.

Copyright © 2019 by Nur Imanina Binti Abdullah Thaidi and International Islamic University Malaysia. All rights reserved

No part of this unpublished research may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without prior written permission of the copyright holder except as provided below

1. Any material contained in or derived from this unpublished research may only be used by others in their writing with due acknowledgement.

2. IIUM or its library will have the right to make and transmit copies (print or electronic) for institutional and academic purposes.

3. The IIUM library will have the right to make, store in a retrieval system and supply copies of this unpublished research if requested by other universities and research libraries.

By signing this form, I acknowledged that I have read and understand the IIUM Intellectual Property Right and Commercialization policy.

Affirmed by Nur Imanina Binti Abdullah Thaidi

........................................  ....................................
Signature                  Date
This thesis is dedicated for my source of inspiration which is my beloved husband,
parents and daughter; may Allah SWT grant them jannatul-firdaus.
ACKNOWLEDGEMENTS

In the name of Allah, The Most Gracious, The Most Merciful. Alhamdulillah, it is only His blessing that I could finish my thesis.

I would like to express my gratitude to my supervisor Asst. Prof Dr. Normah Haron who provide me the opportunity to doing this research, guidance and give direction to achieve the goals. Without her guidance and help this dissertation would not have been possible.

Furthermore, I would like to express my appreciation to my rest co-supervisor, Asst. Prof Dr. Hanapi Mat Jusoh and Assoc. Prof Dr Deny Susanti for their encouragements and advices related to the study.

I also would like to acknowledge Centre for Postgraduate Study and International Islamic University Malaysia for the financial support, to all staff in Kulliyyah of science and staff of Postgraduate study office for assisting me during the study, May Allah bless them and their family always.

Finally, I’m pleased to express my deepest appreciation to my lovely parents, Kalsom and Abdullah Thaidi, and my husband, Dr. Ahmad Badruddin, for always make Dua’, encouraged and supported me throughout my study. My daughter Amina Hatice, who always give me strength to finish my research and to all of my colleagues, Afifah, Najwa, Hasyiqin, Syazwani and others, whose I’m indebted for their support.
# TABLE OF CONTENTS

Abstract .......................................................................................................................... ii  
Abstract in Arabic ........................................................................................................ iii  
Approval Page ............................................................................................................... iv  
Declaration ..................................................................................................................... v  
Copyright ...................................................................................................................... vi  
Acknowledgement ........................................................................................................ ix  
Table of Contents ......................................................................................................... xv  
List of Tables ............................................................................................................ xviii  
List of Figures ............................................................................................................. xix  
List of Symbols ......................................................................................................... xixv  
List of Abbreviation ................................................................................................... xvii  

## CHAPTER ONE INTRODUCTION ......................................................................... 1  
  1.1 Background ................................................................................................... 1  
  1.2 Problem Statement and Its Significance ....................................................... 2  
  1.3 Research Objectives ...................................................................................... 4  
  1.4 Research Methodology ................................................................................. 4  
  1.5 Dissertation Organisation ............................................................................. 5  

## CHAPTER TWO LITERATURE REVIEWS .......................................................... 7  
  2.1 Diabetes Mellitus .......................................................................................... 7  
      2.1.1 Classification of Diabetes .................................................................. 7  
      2.1.1.1 Type 1 Diabetes Mellitus ................................................................. 8  
      2.1.1.2 Type 2 Diabetes Mellitus ................................................................. 8  
      2.1.1.3 Gestational Diabetes Mellitus ....................................................... 9  
      2.1.1.4 Specific Types of Diabetes Due to Other Causes ....................... 10  
      2.1.2 Risk Factors of Type 2 Diabetes Mellitus ........................................ 11  
      2.1.3 Complications of Type 2 Diabetes Mellitus .................................... 12  
      2.1.4 Prevalence of Diabetes Mellitus in Malaysia ................................... 13  
  2.2 Mechanism and Pathophysiology of T2DM ............................................... 13  
      2.2.1 Glucose Homeostasis ....................................................................... 14  
      2.2.2 Genetic Factors ................................................................................. 15  
      2.2.3 β-Cell Function ................................................................................ 15  
      2.2.4 Insulin Resistance ............................................................................ 16  
  2.3 Therapeutic Approach Towards T2DM ...................................................... 17  
      2.3.1 Antidiabetic Drugs ........................................................................... 19  
      2.3.1.1 Biguanide ..................................................................................... 19  
      2.3.1.2 Sulfonylureas ............................................................................... 19  
      2.3.1.3 The DPPIV Inhibitors ................................................................. 20  
      2.3.1.4 Thiazolidinediones .................................................................... 20  
      2.3.1.5 Alpha-Glucosidase Inhibitors .................................................... 20  
      2.3.1.6 Insulin ...................................................................................... 20  
  2.4 Enzymes ...................................................................................................... 21
2.4.1 The α-Amylase ................................................................. 21
  2.4.1.1 Acarbose as a Known α-Amylase Inhibitor ................. 23
2.4.2 The Dipeptidyl Peptidase IV .............................................. 23
  2.4.2.1 The DPPIV Inhibitor .................................................. 24
2.5 Medicinal Plants with Antidiabetic Properties ....................... 26
2.6 Role of Plant Secondary Metabolites in Diabetes Managements ... 28
  2.6.1 Effects of Polyphenols on α-Amylase and DPPIV .......... 30
2.7 Anacardium Occidentale Linn. ............................................. 32
  2.7.1 Bioactive Polyphenols in A. Occidentale L. Leaves .......... 35
  2.7.2 A. Occidentale L. As Potential Anti-Diabetic and Anti-
                  Hyperglycemic ......................................................... 35
2.8 Summary .......................................................................... 36

CHAPTER THREE MATERIALS AND METHODS .................................. 38
  3.1 Experimental Materials ..................................................... 38
  3.1.1 Chemicals, Reagents, and Enzymes .............................. 38
  3.1.2 Instruments .................................................................. 38
  3.1.3 Consumable Items ....................................................... 39
  3.1.4 Samples Material .......................................................... 39
       3.1.4.1 Pre-Treatment of Plant Samples ................................. 40
  3.2 Sample Extraction ............................................................... 40
       3.2.1 Free Phenolic Fraction .............................................. 41
       3.2.2 Soluble Ester Phenolic Fraction ................................. 41
       3.2.3 Insoluble Bound Phenolic Fraction ............................ 42
  3.3 High-Performance Liquid Chromatography (HPLC) Analysis ... 42
  3.4 In Vitro α-Amylase Inhibition Analysis ............................... 43
       3.4.1 Preparation 3,5-Dinitrosalicylic Acid (DNSA) Reagent ... 43
       3.4.2 The α-Amylase Inhibition Study ................................. 44
  3.5 In Vitro Dipeptidyl Peptidase IV (DPPIV) Inhibition Analysis ... 46
       3.5.1 Signal Stability of The Assay ..................................... 46
       3.5.2 Selection of Positive Control .................................... 46
       3.5.3 The DPPIV Inhibition Study .................................... 47
  3.6 Statistical Analysis ............................................................ 49

CHAPTER FOUR RESULTS AND DISCUSSION ..................................... 50
  4.1 Introduction ................................................................. 50
  4.2 Extraction on Phenolic Fractions of Leaves Samples ............... 50
  4.3 Identification and Quantification of Polyphenols ..................... 54
       4.3.1 Chromatograms of Bioactive Polyphenols in A. Occidentale L .... 54
       4.3.2 Statistical Analysis Of Bioactive Polyphenols Analyzed by HPLC-
           Uv-Vis ........................................................................ 63
  4.4 In Vitro Study of α-Amylase and DPPIV Inhibition Activities ..... 68
       4.4.1 In Vitro α-Amylase Inhibition Study ......................... 68
         4.4.1.1 Observation of Color Change in α-Amylase Study .......... 68
         4.4.1.2 Standard Calibration Curve of Maltose by the
                  spectrophotometer .................................................. 70
         4.4.1.3 Percentage of Inhibition of α-Amylase in the Presence of
                  Compounds Extracted From A. Occidentale L ............... 72
       4.4.2 In Vitro DPPIV Inhibition Study .............................. 73

xvi
# LIST OF TABLES

<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table 3.1</td>
<td>Condition of HPLC for Selected Standards</td>
<td>43</td>
</tr>
<tr>
<td>Table 4.1</td>
<td>Total Yield (%) of Phenolic Fractions in Young and Mature of Leaves.</td>
<td>50</td>
</tr>
<tr>
<td>Table 4.2</td>
<td>Concentration of Dry Weight (µg/g) of Polyphenols in Three Fraction of Leaves <em>A. occidentale</em> L.</td>
<td>64</td>
</tr>
<tr>
<td>Table 4.3</td>
<td>Percentage (%) of Leaves <em>A. occidentale</em> L. (0.6 mg/ml) on α-Amylase Inhibition by Maturity.</td>
<td>72</td>
</tr>
<tr>
<td>Table 4.4</td>
<td>IC₅₀ (µg/ml) Value of Leaves <em>A. occidentale</em> L. on DPPIV Inhibition by Maturity.</td>
<td>75</td>
</tr>
</tbody>
</table>
LIST OF FIGURES

Figure 1.1 Flowchart of Experimental Studies. 5
Figure 2.1 The Structural Formula of Sitagliptin and Vildagliptin as Well as for Saxagliptin and Alogliptin. 25
Figure 2.2 Tree of A. occidentale L. 33
Figure 2.3 Young Leaves of A. occidentale L. 34
Figure 2.4 Mature Leaves of A. occidentale L. 34
Figure 3.1 A. occidentale L. Extract on α-Amylase Inhibition Study in 96-Well Plate. 45
Figure 3.2 Signal Stability Assay in White 96-Well Plate. 46
Figure 3.3 Selection Positive Control in White 96-Well Plate. 47
Figure 3.4 DPPIV Inhibition Study Assay in White 96-Well Plate. 49
Figure 4.1 Chromatogram of Gallic Acid Standard for Calibration in HPLC. 55
Figure 4.2 Chromatogram of Ferulic Acid Standard for Calibration in HPLC. 55
Figure 4.3 Chromatogram of p-Coumaric Acid Standard for Calibration in HPLC. 56
Figure 4.4 Chromatogram of Kaempferol Standard for Calibration in HPLC. 56
Figure 4.5 Chromatogram of Quercetin Standard from Calibration in HPLC. 56
Figure 4.6 Chromatograms of the Free Phenolic of Young Leaves with Gallic Acid Presented. 57
Figure 4.7 Chromatogram of the Free Phenolic of Mature Leaves with Gallic Acid Presented. 58
Figure 4.8 Chromatogram of the Soluble Ester of Mature Leaves with Gallic Acid Presented. 58
Figure 4.9  Chromatogram of the Insoluble Bound of Mature Leaves with Gallic Acid Presented.  58
Figure 4.10  Chromatogram of the Soluble Ester of Young Leaves with Gallic Acid Presented.  59
Figure 4.11  Chromatogram of the Free Phenolic of Mature Leaves with Ferulic Acid Presented.  59
Figure 4.12  Chromatogram of the Free Phenolic of Young Leaves with Ferulic Acid Presented.  60
Figure 4.13  Chromatogram of the Soluble Ester of Young Leaves with Ferulic Acid Presented.  60
Figure 4.14  Chromatogram of the Free Phenolic of Mature Leaves with p-Coumaric Acid Presented.  60
Figure 4.15  Chromatogram of the Insoluble Bound of Mature Leaves with p-Coumaric Acid Presented.  61
Figure 4.16  Chromatogram of the Free Phenolic of Young Leaves with p-Coumaric Acid Presented.  61
Figure 4.17  Chromatogram of the Soluble Ester of Young Leaves with p-Coumaric acid Presented.  61
Figure 4.18  Chromatogram of the Free Phenolic of Mature Leaves with Kaempferol.  62
Figure 4.19  Chromatogram of the Free Phenolic of Young Leaves with Kaempferol.  62
Figure 4.20  Chromatogram of the Free Phenolic of Mature Leaves with Quercetin.  62
Figure 4.21  Chromatogram of the Free Phenolic of Young Leaves with Quercetin.  63
Figure 4.22  Comparison of Polyphenols by Fraction in Young Leaves, Values are Expressed as the Mean ±SEM (n=3).  66
Figure 4.23  Comparison of Polyphenols by Fraction in Mature Leaves, Values are Expressed as the Mean ±SEM (n=3).  67
Figure 4.24  Color Change of Young Leaves Sample After Boiled with DNSA Reagent.  69
Figure 4.25  Color Change of Mature Leaves Sample After Boiled with DNSA Reagent. 69

Figure 4.26  Standard Calibration Curve of Maltose (0-0.25 mg/ml). 71

Figure 4.27  IC_{50} of Kaempferol (Positive Control) in DPPIV Inhibition. 74

Figure 4.28  Comparison by Phenolic Fractions on α-Amylase Inhibition Activities, Values are Expressed as Mean ±SEM. 79

Figure 4.29  Comparison by Phenolic Fractions on DPPIV Inhibition Activities, Values are Expressed as Mean ±SEM 80

Figure 4.30  Multivariate Analysis of Variance of *A. occidentale* L. Extracts on α-Amylase Inhibition Study, Values are Expressed as Mean ±SEM 82

Figure 4.31  Multivariate Analysis of Variance of *A. occidentale* L. Extracts on DPPIV Inhibition Study, Values are Expressed as Mean ±SEM 82
# LIST OF SYMBOLS

<table>
<thead>
<tr>
<th>Symbol</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;</td>
<td>Substitution</td>
</tr>
<tr>
<td>g</td>
<td>Gravitational force</td>
</tr>
<tr>
<td>ml</td>
<td>Milliliter</td>
</tr>
<tr>
<td>µl</td>
<td>Microlitre</td>
</tr>
<tr>
<td>ºC</td>
<td>Degree Celsius</td>
</tr>
<tr>
<td>%</td>
<td>Percentage/proportion</td>
</tr>
<tr>
<td>≥</td>
<td>Greater than or equal to</td>
</tr>
<tr>
<td>ng/µl</td>
<td>Nanogram per litre</td>
</tr>
<tr>
<td>U/ml</td>
<td>Units per milliliter</td>
</tr>
<tr>
<td>mg</td>
<td>Milligram</td>
</tr>
<tr>
<td>±</td>
<td>Plus-minus</td>
</tr>
<tr>
<td>µM</td>
<td>Micromolar</td>
</tr>
<tr>
<td>*</td>
<td>Asterisk</td>
</tr>
<tr>
<td>µg</td>
<td>Microgram</td>
</tr>
<tr>
<td>α</td>
<td>Alpha</td>
</tr>
<tr>
<td>β</td>
<td>Beta</td>
</tr>
<tr>
<td>hr</td>
<td>Hour</td>
</tr>
<tr>
<td>kDa</td>
<td>Kilodalton</td>
</tr>
<tr>
<td>Kg/m²</td>
<td>Kilogram per square meter</td>
</tr>
<tr>
<td>L</td>
<td>Liter</td>
</tr>
<tr>
<td>min</td>
<td>Minute</td>
</tr>
</tbody>
</table>
**LIST OF ABBREVIATIONS**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANOVA</td>
<td>Analysis of variance</td>
</tr>
<tr>
<td>BMI</td>
<td>Body mass index</td>
</tr>
<tr>
<td>DMSO</td>
<td>Dimethylsulfoxide</td>
</tr>
<tr>
<td>DNA</td>
<td>Deoxyribonucleic acid</td>
</tr>
<tr>
<td>DPPH</td>
<td>2,2-diphenyl-1-picrylhydrazyl</td>
</tr>
<tr>
<td>DPPIV</td>
<td>Dipeptidyl peptidase IV</td>
</tr>
<tr>
<td>e.g.</td>
<td>exempli gratia; for example</td>
</tr>
<tr>
<td>et al.</td>
<td>et alia; and others</td>
</tr>
<tr>
<td>FTIR</td>
<td>Fourier transform infrared spectroscopy</td>
</tr>
<tr>
<td>GAE</td>
<td>Gallic acid equilibrium</td>
</tr>
<tr>
<td>GC-MS</td>
<td>Gas chromatography- mass spectrometry</td>
</tr>
<tr>
<td>GDM</td>
<td>Gestational diabetes mellitus</td>
</tr>
<tr>
<td>GIP</td>
<td>Gastric inhibitory peptide</td>
</tr>
<tr>
<td>GLP-1</td>
<td>Glucagon like peptide- 1</td>
</tr>
<tr>
<td>H₂O</td>
<td>Water</td>
</tr>
<tr>
<td>HbA1c</td>
<td>Hemoglobin A1c</td>
</tr>
<tr>
<td>HCl</td>
<td>Hydrochloric acid</td>
</tr>
<tr>
<td>HPLC</td>
<td>High performance chromatography</td>
</tr>
<tr>
<td>LC-MS</td>
<td>Liquid chromatography- mass spectrometry</td>
</tr>
<tr>
<td>M</td>
<td>Molarity</td>
</tr>
<tr>
<td>MeOH</td>
<td>Methanol</td>
</tr>
<tr>
<td>MOH</td>
<td>Ministry of health</td>
</tr>
<tr>
<td>mRNA</td>
<td>messenger Ribonucleic acid</td>
</tr>
<tr>
<td>N</td>
<td>Normality</td>
</tr>
<tr>
<td>NaOH</td>
<td>Sodium hydroxide</td>
</tr>
<tr>
<td>NHMS</td>
<td>National Health Morbidity Survey</td>
</tr>
<tr>
<td>nm</td>
<td>Nanometers</td>
</tr>
<tr>
<td>NMR</td>
<td>Nuclear Magnetic resonance</td>
</tr>
<tr>
<td>PFTE</td>
<td>Polytetrafluoroethylene</td>
</tr>
<tr>
<td>R²</td>
<td>Coefficient of determination</td>
</tr>
<tr>
<td>Rpm</td>
<td>Revolution per minute</td>
</tr>
<tr>
<td>SEM</td>
<td>Standard error of means</td>
</tr>
<tr>
<td>T2DM</td>
<td>Type 2 Diabetes Mellitus</td>
</tr>
<tr>
<td>UV-Vis</td>
<td>Ultraviolet-visible</td>
</tr>
<tr>
<td>v/v</td>
<td>Volume per volume</td>
</tr>
<tr>
<td>WHO</td>
<td>World health organization</td>
</tr>
</tbody>
</table>
CHAPTER ONE

INTRODUCTION

1.1 BACKGROUND

Diabetes mellitus is one of the major health problems that affect millions of people worldwide. It is projected that 642 million people aged 20-79 years around the globe will suffer from diabetes by 2040 (Ogurtsova et al., 2017). In Malaysia, since the first National Health Morbidity Survey (NHMS I) until recent NHMS V, the prevalence of diabetes mellitus among adult population has markedly increased from 6.3% in 1986, 8.2% in 1996, 11.6% in 2006 and 15.2% in 2011 to 17.5% in 2015 (IPH, 1997; Kementerian Kesihatan Malaysia 2015). Besides, diabetes also becomes one of the leading causes of death globally (Ogurtsova et al., 2017). In 2012, it was reported that diabetes has caused 1.5 million (2.7%) deaths (World Health Organization, 2016).

The management of diabetes involves continuous medical care with the number of factors risk reduction strategies including lifestyle modifications and treatments with synthetic hypoglycaemic drugs. Yet, it is estimated that 70-80% of the world populations still depending heavily on alternative medicine such as traditional herbs to encounter their primary health care needs, including treatments for diabetes, particularly in rural areas of developing states (World Health Organization, 2002). For example, plants such as *Aloe vera*, *Andrographis paniculate* (Green chiretta), *Centella asiatica* (Asiatic pennywort), *Curcuma longa* (Turmeric) and *Anacardium occidentale* (Cashew) have been demonstrated to possess antidiabetic properties (Esimone et al., 2001; Mustaffa et al., 2011; Obaineh, 2013), owing to the existence of bioactive
compounds that act as antidiabetic agents such as carotenoids and polyphenols (Shukri et al., 2011).

1.2 PROBLEM STATEMENT AND ITS SIGNIFICANCE

Medicinal plants are good sources as alternative or complementary treatments for diabetes and other diseases (Eddouks, Chattopadhyay, De Feo, & Cho, 2014; Jamila & Mostafa, 2014; Mardani, Nasri, Rafieian-Kopaei, & Hajian, 2013). Although various plants have been traditionally used throughout history to reduce blood glucose and improve diabetes complications, there is not enough scientific information about some of them such as *Anacardium occidentale* L..

*Anacardium occidentale* Linn. (*A. occidentale* L.) or commonly known as cashew tree, is a popular tropical plant among Malaysian for its leaves, the cashew seed, and the cashew apple. Its young leaves are notably one of the commonly consumed vegetables by various ethnics such as Malays, Chinese, and Indian in Malaysia (Shukri et al., 2010).

As described earlier, the leaves of *A. occidentale* L. also possess an excellent source of bioactive compounds including polyphenols such as phenolic acids and flavonoids (Malviya, Jain, & Malviya, 2010; Nugroho, Malik, & Pramono, 2013; Ojezele & Agunbiade, 2013). Alkali and water extracts of *A. occidentale* L. contained predominantly gallic acid as well as protocatechuic, *p*-hydroxybenzoic, cinnamic, *p*-coumaric and ferulic acids (Kögel & Zech, 1985). Furthermore, extract of cashew shoots has been identified to have flavonol glycoside, with the highest constituent of kaempferol-3-O-glucoside, followed by kaempferol-3-O-arabinofuranoside and quercetin-3-O-glucoside (Shukri & Alan, 2010).
In the carbohydrate metabolism, polyphenols such as phenolic acids, flavonoids, and tannins play a role in inhibiting α-amylase, a glycoside hydrolase enzyme that if attenuated can slow down the breakdown of long-chain carbohydrates to glucose, this leads to a reduction in the rate at which glucose enters the bloodstream, thus preventing a sudden rise in postprandial blood glucose levels (Jang & Moon, 2011; Laughlin et al., 1995; Nair, Kavrekar, & Mishra, 2013; Ranilla, Kwon, Apostolidis, & Shetty, 2010).

Polyphenols are also able to regulate postprandial glucose levels through the inhibition of Dipeptidyl peptidase IV (DPPIV), a serine protease that localizes on the cell surface of various tissues, including small intestine (Avila et al., 2017). By inhibiting DPPIV, it prevents the rapid degradation of incretins such as glucagon-like peptide 1 (GLP-1) and gastric inhibitory peptide (GIP) that play a vital role in blood glucose control. GLP-1 and GIP actions include stimulating insulin secretion, lowering glucagon concentration and slowing gastric emptying (Barnett, 2006; Nadkarni, Chepurny, & Holz, 2014).

For this reason, this study sought to determine whether *A. occidentale* leaves extracts to play a role in the inhibition of α-amylase and DPPIV enzymes. Here we compared the enzyme-inhibitory activities of the extracts between free, soluble esters, and insoluble bound phenolic fractions as well as between young and mature leaves. It is anticipated that these findings could provide some possible mechanisms by which they are used in the management and prevention of type 2 diabetes mellitus.
1.3 RESEARCH OBJECTIVES

The main objective of this study was to investigate the role of bioactive compounds from *A. occidentale* L. in inhibiting of α-amylase and dipeptidyl peptidase IV (DPPIV).

In order to achieve the main objective, this project was subdivided into several specific objectives:

1. To extract free, soluble ester and insoluble bound of phenolic fractions of young and mature leaves of *A. occidentale* L.
2. To identify and quantify the polyphenols compounds (selected phenolic compounds) using HPLC-UV-Vis.
3. To determine bioactivities of leaves of *A. occidentale* L. on inhibition of α-amylase and DPPIV enzymes by maturity of leaves and phenolic fractions.

1.4 RESEARCH METHODOLOGY

The research was a laboratory-based experimental work use the young and mature leaves of *A. occidentale* L. to discover the potential to inhibit α-amylase and DPPIV.

The flowchart of experimental studies is shown in Figure 1.1. The detailed methodology is described in chapter three of the thesis.
Figure 1.1 Flowchart of Experimental Studies.

1.5 DISSERTATION ORGANISATION

Chapter one is about an introduction to the research, provided with the background of the study, problem statements, and objectives. Chapter two is about the review of the literature concerning diabetes, therapeutic approach, enzymes, previous research on enzymes, medicinal plants, *A. occidentale* L., and polyphenols content in *A. occidentale* L.. Chapter three provides the materials and method used in the study. Chapter four presents the results and discusses the findings obtained from the research work with several comparisons from the previous research. Last but not least, chapter
five is about the conclusion by the objectives coupled with future recommendations on how to improve research.
2.1 DIABETES MELLITUS

Diabetes mellitus (DM) cases are arising in the 21st century, and it is one of the major causes of death in humans after AIDS, cancer, and cerebrovascular diseases (Dey, Mitra, Katakam, & Singla, 2014). It has been projected that 642 million people aged 20-79 years around the globe would suffer from diabetes by the year 2040, and diabetes will be one of the major causes of death globally (Ogurtsova et al., 2017).

Diabetes mellitus is a complex metabolic disorder, and patients diagnosed with it require continuous medical care and clinical appointments with treatment aiming towards multifactorial risk reduction plans beyond glycaemic control (Cameron, 2006). A lot of numbers of diabetes are producing and showing no symptom (Olokoba, Obateru, & Olokoba, 2012). However, common symptoms include increased thirst, polydipsia, increased frequency of urination, fatigue, loss of weight, blurred vision and increased risk of infection (Nolan, Damm, & Prentki, 2011).

2.1.1 Classification of Diabetes

Classification of diabetes is essential to step in selecting therapeutic management. The classical classification of diabetes mellitus is type 1 and type 2. However, some individuals are not able to be classified as suffering from type 1 or type 2 diabetes during the first clinical check-up. The traditional paradigms are type 2 diabetes exclusive in adulthood and type 1 diabetes exclusive in childhood are not entirely